WO2000076552A8 - Methods and compositions for control of bone formation via modulation of leptin activity - Google Patents

Methods and compositions for control of bone formation via modulation of leptin activity

Info

Publication number
WO2000076552A8
WO2000076552A8 PCT/US2000/015911 US0015911W WO0076552A8 WO 2000076552 A8 WO2000076552 A8 WO 2000076552A8 US 0015911 W US0015911 W US 0015911W WO 0076552 A8 WO0076552 A8 WO 0076552A8
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
compositions
methods
control
bone formation
Prior art date
Application number
PCT/US2000/015911
Other languages
French (fr)
Other versions
WO2000076552A1 (en
Inventor
Gerard Karsenty
Patricia Ducy
Michael Amling
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Priority to JP2001502883A priority Critical patent/JP2003528804A/en
Priority to AU56031/00A priority patent/AU767068B2/en
Priority to CA002376933A priority patent/CA2376933A1/en
Priority to EP00941311A priority patent/EP1191945A4/en
Publication of WO2000076552A1 publication Critical patent/WO2000076552A1/en
Publication of WO2000076552A8 publication Critical patent/WO2000076552A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the method for treatment, diagnosis and prevention of bone disease and comprises methods including inhibiting or increasing leptin synthesis, leptin receptor synthesis, leptin binding to the leptin receptor, and leptin receptor activity. The invention also relates to screening assays to identify compounds that modulate leptin and/or leptin receptor activity. The invention further relates to gene therapy methods utilizing leptin and leptin-related sequences for the treatment and prevention of bone disease.
PCT/US2000/015911 1999-06-11 2000-06-09 Methods and compositions for control of bone formation via modulation of leptin activity WO2000076552A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001502883A JP2003528804A (en) 1999-06-11 2000-06-09 Methods and compositions for controlling bone formation through modulation of leptin activity
AU56031/00A AU767068B2 (en) 1999-06-11 2000-06-09 Methods and compositions for control of bone formation via modulation of leptin activity
CA002376933A CA2376933A1 (en) 1999-06-11 2000-06-09 Methods and compositions for control of bone formation via modulation of leptin activity
EP00941311A EP1191945A4 (en) 1999-06-11 2000-06-09 Methods and compositions for control of bone formation via modulation of leptin activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13873399P 1999-06-11 1999-06-11
US60/138,733 1999-06-11
US16044199P 1999-10-19 1999-10-19
US60/160,441 1999-10-19
US48987300A 2000-01-20 2000-01-20
US09/489,873 2000-01-20

Publications (2)

Publication Number Publication Date
WO2000076552A1 WO2000076552A1 (en) 2000-12-21
WO2000076552A8 true WO2000076552A8 (en) 2001-07-05

Family

ID=27385218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015911 WO2000076552A1 (en) 1999-06-11 2000-06-09 Methods and compositions for control of bone formation via modulation of leptin activity

Country Status (4)

Country Link
EP (1) EP1191945A4 (en)
JP (1) JP2003528804A (en)
CA (1) CA2376933A1 (en)
WO (1) WO2000076552A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169559B2 (en) 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
DE10353593A1 (en) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptin antagonist and method for the quantitative measurement of leptin
JP2006094720A (en) * 2004-09-28 2006-04-13 Nakamura Sangyo Gakuen Substrate for bone cell culture and method for bone cell culture
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698389A (en) * 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
EP0917469A1 (en) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Methods for inducing bone formation
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
WO1999053939A1 (en) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin

Also Published As

Publication number Publication date
CA2376933A1 (en) 2000-12-21
JP2003528804A (en) 2003-09-30
EP1191945A1 (en) 2002-04-03
WO2000076552A1 (en) 2000-12-21
EP1191945A4 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
WO2005115435A3 (en) Methods and compositions for control of fetal growth via modulation of relaxin
EP0911321A3 (en) Compounds for the treatment of osteoporosis
WO1998040055A3 (en) Anti-epileptogenic agents
WO2006012627A3 (en) Actrii receptor polypeptides, methods and compositions
WO2002038107A3 (en) Stat modulators
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2001001748A3 (en) Peptide compounds that bind her2
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
WO2000006085A3 (en) Compounds and methods
AU4981500A (en) Cancer treatment with endothelin receptor antagonists
AU6416198A (en) Diagnostic means useful for predictive assessment of human hepatocellular carc inoma disease (hcc), as well as diagnostic methods using the same
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
NO20055309D0 (en) Slurp-1 coagulation schemes and methods for using them
WO2002073208A3 (en) Anti-epileptogenic agents
WO2002022871A3 (en) Polymorphic bone morphogenetic protein 2
WO2002039118A8 (en) Screening methods for bone morphogenetic mimetics
WO2000076552A8 (en) Methods and compositions for control of bone formation via modulation of leptin activity
WO2004048522A3 (en) Modulation of huntingtin interacting protein 2 expression
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
EP1185696A4 (en) Antisense oligonucleotide modulation of human protein kinase c-delta expression
MXPA02001204A (en) Calcilytic compounds.
WO2004043394A3 (en) Modulation of huntingtin interacting protein 1 expression
WO2002064021A3 (en) Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 51/2000 UNDER (30) ADD "60/160441, 19.10.99, US"

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 502883

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2376933

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 56031/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000941311

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000941311

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000941311

Country of ref document: EP